MedTrace Logo

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

NCT00375401 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2536

Last updated 2012-11-07

No results posted yet for this study

Summary

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

Conditions

Interventions

DRUG

CP-945,598 Treatment A

Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling

DRUG

CP-945,598 Treatment B

Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling

DRUG

Placebo

Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375401 on ClinicalTrials.gov